Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q3 2023 Pharma Services Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q3 2023 Pharma Services Update

Despite an uncertain macroeconomic environment, rising interest rates, political headwinds in Washington, and the impact of tightening credit markets, M&A activity in pharma services displayed strong resiliency in Q3-23, fueled by platform investments and dozens of add-on acquisitions. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including cash-rich sponsors and CROs, reducing costs, technological advancements, and access to value-added specialty services. Large pharma services conglomerates continue to diversify their service offerings to de-risk revenue concentration and provide more full-service solutions for their clients and patients.

Provident expects pharma service M&A activity to remain strong in Q4 and in 2024 as companies look to fill the potential growth gap from the $100B in patents set to expire by 2030, and PE sponsors begin to exit more mature portfolio companies.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/10/Q3-23-Pharma-Services.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]